Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab versus placebo in previously treated unresectable malignant mesothelioma
NL-OMON41613Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mesothelioma, pleural mesothelioma and peritoneal mesothelioma comparing Tremelimumab with Placebo (2 arms). Primary endpoint: Overall survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
tremelimumab
03
Conditions
mesotheliomapleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on NL-OMON41613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41613.